The company came out with very strong earnings – 12% growth y-o-y. Despite the run in share prices currently, he thinks there is still lots of runway. The companies touches on so many aspects of public health in the US and suggests politicians will avoid public cuts in spending going forward. He sees their growth continuing. Yield 1.3%.
The company came out with very strong earnings – 12% growth y-o-y. Despite the run in share prices currently, he thinks there is still lots of runway. The companies touches on so many aspects of public health in the US and suggests politicians will avoid public cuts in spending going forward. He sees their growth continuing. Yield 1.3%.
This is a very positive company. This is a large US insurer, with a separate interest in health records and technology. The company has done very well but still trades at a reasonable valuation.
This is a very positive company. This is a large US insurer, with a separate interest in health records and technology. The company has done very well but still trades at a reasonable valuation.
Its technicals and fundamentals have nicely converged and is now perfectly priced. There's no upside or downside here. No momentum to rise. Maybe in another year there'll be enough earnings.
Its technicals and fundamentals have nicely converged and is now perfectly priced. There's no upside or downside here. No momentum to rise. Maybe in another year there'll be enough earnings.
Healthcare is in a secular bull market. Fantastsic trend upwards over the past year. Executing well. (Analysts' price target: $280.23)
Healthcare is in a secular bull market. Fantastsic trend upwards over the past year. Executing well. (Analysts' price target: $280.23)
(A Top Pick September 14/17 - Up 27%.) A tremendous growth story. Still a holding. Dominant leaders in the space.
(A Top Pick September 14/17 - Up 27%.) A tremendous growth story. Still a holding. Dominant leaders in the space.
(A Top Pick June 13/17 Up 29%) He sees no reason to move away from this holding. It is a consistent performer and will continue to do well. The independant gorilla in the Medicare and Medicaid space in the US. Did have a little bit of a pullback and consolidation. A very positive story and good momentum based on last quarter earnings.
(A Top Pick June 13/17 Up 29%) He sees no reason to move away from this holding. It is a consistent performer and will continue to do well. The independant gorilla in the Medicare and Medicaid space in the US. Did have a little bit of a pullback and consolidation. A very positive story and good momentum based on last quarter earnings.
(A Top Pick May 10/17, Up 30%) Pure health insurance in the U.S. and expects it be the dominant player. Made a tremendous acquisition 2012 that's paid off. Stock is a great performer, and he likes the sector, too, which will consolidate.
(A Top Pick May 10/17, Up 30%) Pure health insurance in the U.S. and expects it be the dominant player. Made a tremendous acquisition 2012 that's paid off. Stock is a great performer, and he likes the sector, too, which will consolidate.
Amazon, Berkshire Hathaway and J.P. Morgan just announced forming a healthcare company aimed at cutting costs. The experiment with government led healthcare mandates really didn’t work. There was far too much friction between opposing views. If you own the stock, you shouldn't get too excited about just one day, or the fact that insurers are going to go away.
Amazon, Berkshire Hathaway and J.P. Morgan just announced forming a healthcare company aimed at cutting costs. The experiment with government led healthcare mandates really didn’t work. There was far too much friction between opposing views. If you own the stock, you shouldn't get too excited about just one day, or the fact that insurers are going to go away.
(A Top Pick Jun 13/17, Up 23%) They have a couple of headwinds right now. There is a health insurer thing rolling off that is a one year thing. He continues to like them.
(A Top Pick Jun 13/17, Up 23%) They have a couple of headwinds right now. There is a health insurer thing rolling off that is a one year thing. He continues to like them.
(A Top Pick June 13/17. Up 18%.) This has been an absolute hero. It has several tailwinds. It is the dominant Medicare/Medicaid provider. Management is intent on returning 50% of free cash flow. It has all the right factors. He still likes this.
(A Top Pick June 13/17. Up 18%.) This has been an absolute hero. It has several tailwinds. It is the dominant Medicare/Medicaid provider. Management is intent on returning 50% of free cash flow. It has all the right factors. He still likes this.
A fine company, but his choice has been Anthem (ANTM-N). Has great admiration for this company. They are very good managers. They have the attributes that are really important from a risk/rewards standpoint in the healthcare insurance space, and that is size and scale. They have enough risk aversion that you should be safe holding this.
A fine company, but his choice has been Anthem (ANTM-N). Has great admiration for this company. They are very good managers. They have the attributes that are really important from a risk/rewards standpoint in the healthcare insurance space, and that is size and scale. They have enough risk aversion that you should be safe holding this.
The dominant player in health insurance in the US. They have a pharmacy benefit manager. They are squeezing down costs and gaining business. (Analysts’ target: $214.00).
The dominant player in health insurance in the US. They have a pharmacy benefit manager. They are squeezing down costs and gaining business. (Analysts’ target: $214.00).
(A Top Pick May 20/16. Up 46.72%.) He’s been really happy with this. This is definitely the leader in their group. Management is intent on returning capital, 50% of earnings and cash flow each year.
(A Top Pick May 20/16. Up 46.72%.) He’s been really happy with this. This is definitely the leader in their group. Management is intent on returning capital, 50% of earnings and cash flow each year.
